Dr. Mary T Jenkins Vogel, MD
Claim this profileNorthShore University HealthSystem-Evanston Hospital
Studies Thyroid Cancer
Studies Ovarian Cancer
13 reported clinical trials
42 drugs studied
Area of expertise
1Thyroid Cancer
Stage I
Stage IV
Stage III
2Ovarian Cancer
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Mary T Jenkins Vogel, MD is currently running
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Mary T Jenkins Vogel, MD
Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Mary T Jenkins Vogel, MD has experience with
- Carboplatin
- Paclitaxel
- Olaparib
- Pembrolizumab
- Biospecimen Collection
- Cediranib Maleate
Breakdown of trials Mary T Jenkins Vogel, MD has run
Thyroid Cancer
Ovarian Cancer
Stomach Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary T Jenkins Vogel, MD specialize in?
Mary T Jenkins Vogel, MD focuses on Thyroid Cancer and Ovarian Cancer. In particular, much of their work with Thyroid Cancer has involved Stage I patients, or patients who are Stage IV.
Is Mary T Jenkins Vogel, MD currently recruiting for clinical trials?
Yes, Mary T Jenkins Vogel, MD is currently recruiting for 6 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that Mary T Jenkins Vogel, MD has studied deeply?
Yes, Mary T Jenkins Vogel, MD has studied treatments such as Carboplatin, Paclitaxel, Olaparib.
What is the best way to schedule an appointment with Mary T Jenkins Vogel, MD?
Apply for one of the trials that Mary T Jenkins Vogel, MD is conducting.
What is the office address of Mary T Jenkins Vogel, MD?
The office of Mary T Jenkins Vogel, MD is located at: NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the NorthShore University HealthSystem-Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.